Intercept Pharma rises on quarterly results beat

Intercept Pharmaceuticals

01/11/2022 14:40

** Shares of Intercept Pharmaceuticals Inc  ICPT.O  up 12%
at $15.5 - making them the fourth highest percentage gainer on
Nasdaq Biotechnology index in morning trade
    ** ICPT beats analysts' revenue and profit estimates, helped
by sales growth of its liver disease drug Ocaliva 
    ** Posts Q3 adj. EPS of $7.80 vs. estimates of $4.61 -
Refinitiv IBES data
    ** Quarterly revenue of $77.6 million vs estimates of $74.1
million
    ** Stock down 5.2% YTD, compared with a 12% decline in the
Nasdaq biotechnology index  .NBI 
 (Reporting by Aditya Samal)
 ((Aditya.Samal@thomsonreuters.com;))